Status:

WITHDRAWN

Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration

Lead Sponsor:

University of Padova

Collaborating Sponsors:

Department of Ophthalmology, Conegliano Hospital, Treviso, Italy

Conditions:

Neovascular Age-related Macular Degeneration

Eligibility:

All Genders

55-80 years

Phase:

PHASE2

Brief Summary

This phase II study was designed to evaluate the safety, tolerability, and efficacy of bevacizumab treatment in conjunction with PDT at the low fluence rate compared with bevacizumab alone or combined...

Eligibility Criteria

Inclusion

  • All lesion subtype of CNV secondary to age-related macular.
  • sub-foveal CNV.
  • patients who fail to respond to Photodynamic therapy.
  • patients who are not eligible for PDT (Greatest linear dimension of the lesion \>/= 5400 um, CNV with hemorrhage \>/= 50 % of the entire lesion, minimally classic or occult CNV with greatest linear dimension of the lesion \>/= 4600 um.).
  • Patients affected by Pigment Epithelium Detachment with CNV.
  • Patients affected by Retinal Angiomatous Proliferation.
  • Willingness and ability to participate and provide written informed consent.

Exclusion

  • Individuals with choroidal neovascularization from causes other than AMD (Myopia, Angioid Streaks).
  • Any intraocular surgery within 2 months in the study eye.
  • Prior retinal or vitreous surgery including posterior segment vitrectomy or scleral buckling in the study eye.
  • Any significant ocular disease that has compromised or could compromise vision in the study eye.
  • Prior stroke, myocardial infarction, or end-stage malignancy.
  • Active hepatitis or clinically significant liver disease, renal failure.
  • Any patient with recent history of new onset cardiac disease or thromboembolic CNS event in the past.
  • Patients who are in an experimental therapy study or who have received experimental therapy within the last 12 weeks.
  • Patients who are a poor medical risk because of other systemic diseases or active uncontrolled infections.

Key Trial Info

Start Date :

January 31 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 31 2008

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00696592

Start Date

January 31 2007

End Date

January 31 2008

Last Update

April 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Ophthalmology, University of Padova

Padua, PD, Italy, 35100